3,922 results match your criteria Hyperphosphatemia


Translation of Nutrient Level Recommendations to Control Serum Phosphate Into Food-Based Advice.

J Ren Nutr 2020 Jul 3. Epub 2020 Jul 3.

Department of Renal Medicine, Cork University Hospital, Cork, Ireland; Health Research Board, Clinical Research Facility, Cork, Ireland.

The control of hyperphosphatemia is key to the management of chronic kidney disease mineral and bone disorder. Dietary restriction of phosphorus is essential to control hyperphosphatemia. Guidelines for chronic kidney disease and end-stage kidney disease generally provide high-level guidance on whether a nutrient should be restricted e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.jrn.2020.04.005DOI Listing

A novel variant in AIRE causing a rare, non‑classical autoimmune polyendocrine syndrome type 1.

Mol Med Rep 2020 Aug 12;22(2):1285-1294. Epub 2020 Jun 12.

Department of Endocrinology, National Health Commission Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P.R. China.

Autoimmune polyendocrine syndrome type 1 (APS‑1) is a rare inherited autoimmune disease, characterized by a classic triad, including chronic mucocutaneous candidiasis, primary adrenocortical insufficiency and hypoparathyroidism. The present study investigated phenotypes and pathogenic variants in a Chinese woman with non‑classical APS‑1. Disease‑associated variants in a patient with APS‑1 were identified via targeted next generation sequencing and the variant was confirmed via Sanger sequencing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/mmr.2020.11227DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339480PMC

EOS789, a novel pan-phosphate transporter inhibitor, is effective for the treatment of chronic kidney disease-mineral bone disorder.

Kidney Int 2020 Apr 23. Epub 2020 Apr 23.

Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.

Chronic kidney disease is characterized as impaired renal function along with the imbalance and dysregulation of mineral metabolism; recognized as chronic kidney disease-mineral and bone disorder. Hyperphosphatemia, characterized by altered phosphate homeostasis along with elevated fibroblast growth factor-23 and intact parathyroid hormone, is such an alteration of mineral metabolism. We discovered a novel inhibitor, EOS789, that interacts with several sodium-dependent phosphate transporters (NaPi-IIb, PiT-1, and PiT-2) known to contribute to intestinal phosphate absorption. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.kint.2020.02.040DOI Listing

Phase 1, First-in-Human Study of Futibatinib, a Highly Selective, Irreversible FGFR1-4 Inhibitor in Patients with Advanced Solid Tumors.

Ann Oncol 2020 Jul 2. Epub 2020 Jul 2.

Medical Oncology, Sarah Cannon Research Institute and Cancer Institute University College London, London, UK.

Background: Futibatinib is an oral, irreversible, highly selective fibroblast growth factor receptor (FGFR)1-4 inhibitor with potent preclinical activity against tumors harboring FGFR aberrations. This first-in-human, phase 1 dose-escalation trial (NCT02052778) evaluates the safety and pharmacokinetics/pharmacodynamics of futibatinib in advanced solid tumors.

Patients And Methods: Following a standard 3+3 dose-escalation design, eligible patients with advanced solid tumors refractory to standard therapies received 8-200 mg futibatinib thrice weekly (TIW) or 4-24 mg once daily (QD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.06.018DOI Listing

Low bone mineral density due to secondary hyperparathyroidism in the mouse model of Fabry disease.

FASEB Bioadv 2020 Jun 10;2(6):365-381. Epub 2020 Jun 10.

Department of Matrix Medicine Faculty of Medicine Oita University Yufu Oita Japan.

Low bone mineral density (BMD)-diagnosed as osteoporosis or osteopenia-has been reported as a new characteristic feature of Fabry disease; however, the mechanism underlying the development of low BMD is unknown. We previously revealed that a mouse model of Fabry disease [] exhibits impaired functioning of medullary thick ascending limb (mTAL), leading to insufficient Ca reabsorption and hypercalciuria. Here, we investigated bone metabolism in mice without marked glomerular or proximal tubular damage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1096/fba.2019-00080DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325589PMC

The Novel -Dihydroperoxide 12AC3O Suppresses High Phosphate-Induced Calcification via Antioxidant Effects in p53LMAco1 Smooth Muscle Cells.

Int J Mol Sci 2020 Jun 29;21(13). Epub 2020 Jun 29.

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, 1-1-1 Gifu 501-1196, Japan.

The excessive intake of phosphate (Pi), or chronic kidney disease (CKD), can cause hyperphosphatemia and eventually lead to ectopic calcification, resulting in cerebrovascular diseases. It has been reported that reactive oxygen species (ROS), induced by high concentrations of Pi loading, play a key role in vascular calcification. Therefore, ROS suppression may be a useful treatment strategy for vascular calcification. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21134628DOI Listing

Biopsy-proven acute phosphate nephropathy: A case report.

World J Clin Cases 2020 Jun;8(12):2585-2589

Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si 13620, Gyeonggi-do, South Korea.

Background: Acute phosphate nephropathy (APN) is a disease that can occur when exposed to high doses of phosphate. The most common cause of APN is the use of oral sodium phosphate for bowel cleansing preparations. However, there are other less commonly known sources of phosphate that are equally important. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12998/wjcc.v8.i12.2585DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322417PMC

A Retrospective Review of Tumor Lysis Syndrome Associated With Colorectal Cancer.

Cureus 2020 May 24;12(5):e8257. Epub 2020 May 24.

Genitourinary Oncology, Creighton University School of Medicine/University of Arizona Cancer Center at Dignity Health, Phoenix, USA.

Tumor lysis syndrome (TLS) is a life-threatening oncologic condition that is most commonly linked with hematologic malignancies and uncommonly seen in solid tumors, including colorectal cancer (CRC). Therefore, a lack of awareness regarding TLS in CRC could lead to significant morbidity and mortality. This study aims to explore the clinical characteristics and outcomes of TLS in patients with CRC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.8257DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313428PMC

DAXX mediates high phosphate-induced endothelial cell apoptosis in vitro through activating ERK signaling.

PeerJ 2020 19;8:e9203. Epub 2020 Jun 19.

Nephrology and Rheumatology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.

Backgroud And Purpose: Hyperphosphatemia, which is a high inorganic phosphate (Pi) level in the serum, promotes endothelial cells dysfunction and is associated with cardiovascular diseases in patients with chronic kidney diseases (CKD). However, the underlying mechanism of high Pi-induced endothelia cell apoptosis remains unclear.

Methods: Human umbilical vein endothelial cells (HUVECs) were treated with normal Pi (1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7717/peerj.9203DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307556PMC

An 8-month-old infant with hypercalcemia and hyperphosphatemia-Answers.

Pediatr Nephrol 2020 Jun 25. Epub 2020 Jun 25.

Division of Pediatric Endocrinology, Department of Pediatrics, Koç University School of Medicine, Istanbul, Turkey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00467-020-04666-5DOI Listing

An 8-month-old infant with hypercalcemia and hyperphosphatemia: Questions.

Pediatr Nephrol 2020 Jun 25. Epub 2020 Jun 25.

Division of Pediatric Endocrinology, Department of Pediatrics, Koç University School of Medicine, Istanbul, Turkey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00467-020-04656-7DOI Listing

Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study.

Nephron 2020 Jun 25:1-12. Epub 2020 Jun 25.

Division of Nephrology, RWTH University Hospital Aachen, Aachen, Germany.

Introduction: Control of hyperphosphatemia in patients on dialysis remains a major challenge.

Objective: This study evaluated predictors of serum phosphorus (sP) control among dialysis patients treated with noncalcium, oral phosphate binder therapy in a phase 3 clinical trial.

Methods: Post hoc analyses were performed using data for patients with hyperphosphatemia who received 52 weeks of treatment with sucroferric oxyhydroxide (SFOH) or sevelamer carbonate (sevelamer). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000507258DOI Listing

Mediation of the relationship between proteinuria and serum phosphate: Insight from the KNOW-CKD study.

PLoS One 2020 22;15(6):e0235077. Epub 2020 Jun 22.

Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea.

Proteinuria and hyperphosphatemia are risk factors for cardiovascular disease in patients with chronic kidney disease (CKD). Although the interaction between proteinuria and the serum phosphate level is well established, the mechanistic link between the two, particularly the extent to which this interaction is mediated by phosphate-regulating factors, remains poorly understood. In this study, we examined the association between proteinuria and the serum phosphate level, as well as potential mediators, including circulating fibroblast growth factor (FGF23)/klotho, the 24-h urinary phosphate excretion rate to glomerular filtration rate ratio (EP/GFR), and the 24-h tubular phosphate reabsorption rate to GFR ratio (TRP/GFR). Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0235077PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307748PMC

Association of serum phosphate concentration with the incidence of intervention for peripheral artery disease in patients undergoing hemodialysis: 10-year outcomes of the Q-Cohort Study.

Atherosclerosis 2020 May 29;304:22-29. Epub 2020 May 29.

Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Background And Aims: Peripheral artery disease (PAD) is mainly caused by atherosclerosis and is a critical cardiovascular complication in patients undergoing hemodialysis. Although hyperphosphatemia is a risk factor for cardiovascular events, whether serum phosphate concentration is associated with PAD remains unclear. This study was performed to clarify the relationship between serum phosphate concentration and the risk of intervention for PAD in patients undergoing hemodialysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosis.2020.04.022DOI Listing

Stimulation of ORAI1 expression, store-operated Ca entry, and osteogenic signaling by high glucose exposure of human aortic smooth muscle cells.

Pflugers Arch 2020 Jun 16. Epub 2020 Jun 16.

Department of Molecular Medicine II, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.

Diabetes and chronic kidney disease (CKD) both trigger vascular osteogenic signaling and calcification leading to early death by cardiovascular events. Osteogenic signaling involves upregulation of the transcription factors CBFA1, MSX2, and SOX9, as well as alkaline phosphatase (ALP), an enzyme fostering calcification by degrading the calcification inhibitor pyrophosphate. In CKD, osteogenic signaling is triggered by hyperphosphatemia, which upregulates the serum and glucocorticoid-inducible kinase SGK1, a strong stimulator of the Ca-channel ORAI1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00424-020-02405-1DOI Listing

Interferences in the measurement of circulating phosphate: a literature review.

Clin Chem Lab Med 2020 Jun 5. Epub 2020 Jun 5.

Department of Internal Medicine, Ente Ospedaliero Cantonale, Locarno, Switzerland.

Background Inorganic phosphate in blood is currently determined by the reaction with molybdate. This report aims at reviewing conditions underlying spuriously altered levels of circulating inorganic phosphate. Content A systematic search of the Excerpta Medica, the National Library Database and the Web of Science database was conducted without language restriction from the earliest publication date available through January 31, 2020. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/cclm-2020-0281DOI Listing

Using 99mTc-(V)-DMSA to follow the vascular calcification process in vascular smooth muscle cells based on pit-1 expression.

Q J Nucl Med Mol Imaging 2020 Jun 15. Epub 2020 Jun 15.

INSERM U1059 Dysfonction Vasculaire et Hémostase, Université de Lyon, UJM-Saint-Etienne, Saint-Étienne, France.

Background: Vascular calcification is an established feature of atherosclerosis process. The sodium/phosphate transporter PiT-1 acts as a biosensor in vascular calcification of VSMCs. [99mTc]-Pentavalent dimercaptosuccinic acid (99mTc-(V)-DMSA) was mediated by PiT-1 transporter in tumoral cells and we propose its evaluation in a vascular calcification in vitro model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S1824-4785.20.03225-2DOI Listing

Route of intestinal absorption and tissue distribution of iron contained in the novel phosphate binder ferric citrate.

Nephrol Dial Transplant 2020 Jun 8. Epub 2020 Jun 8.

Division of Nephrology, University of California Irvine, Irvine, CA, USA.

Background: Anemia of chronic kidney disease (CKD) is, in part, caused by hepcidin-mediated impaired iron absorption. However, phosphate binder, ferric citrate (FC) overcomes the CKD-induced impairment of iron absorption and increases serum iron, transferrin saturation, and iron stores and reduces erythropoietin requirements in CKD/ESRD patients. The mechanism and sites of intestinal absorption of iron contained in FC were explored here. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ndt/gfaa053DOI Listing

Autosomal dominant hypocalcaemia: identification of two novel variants of gene.

BMJ Case Rep 2020 Jun 7;13(6). Epub 2020 Jun 7.

Endocrinology, Diabetes and Metabolism Department, Hospital de Santa Maria, Lisboa, Portugal

Autosomal dominant hypocalcaemia is a rare aetiology of hypocalcaemia, caused by gain-of-function mutations of the calcium-sensing receptor () gene. We present two cases of two asymptomatic women (50-year-old-case 1 and 25-year-old-case 2), referred to our endocrinology department for investigation of hypocalcaemia, hyperphosphatemia and inappropriately low parathormone. Both patients had relatives with the same laboratorial findings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2020-234391DOI Listing

Electrolyte Disorders Induced by Antineoplastic Drugs.

Front Oncol 2020 19;10:779. Epub 2020 May 19.

Unità di Ricerca Cardiorenale, Clinica e Terapia Medica, Dipartimento di Medicina e Chirurgia (DIMEC), University of Parma, Parma, Italy.

The use of antineoplastic drugs has a central role in treatment of patients affected by cancer but is often associated with numerous electrolyte derangements which, in many cases, could represent life-threatening conditions. In fact, while several anti-cancer agents can interfere with kidney function leading to acute kidney injury, proteinuria, and hypertension, in many cases alterations of electrolyte tubular handling and water balance occur. This review summarizes the mechanisms underlying the disturbances of sodium, potassium, magnesium, calcium, and phosphate metabolism during anti-cancer treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.00779DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248368PMC

Vascular Calcification: An Important Understanding in Nephrology.

Vasc Health Risk Manag 2020 12;16:167-180. Epub 2020 May 12.

Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Vascular calcification (VC) is a life-threatening state in chronic kidney disease (CKD). High cardiovascular mortality and morbidity of CKD cases may root from medial VC promoted by hyperphosphatemia. Vascular calcification is an active, highly regulated, and complex biological process that is mediated by genetics, epigenetics, dysregulated form of matrix mineral metabolism, hormones, and the activation of cellular signaling pathways. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/VHRM.S242685DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229867PMC

Seizures and Basal Ganglia Calcification Caused by Hypoparathyroidism.

Cureus 2020 Apr 29;12(4):e7888. Epub 2020 Apr 29.

Pediatrics, Civil Hospital Karachi, Dow University of Health Sciences, Karachi, PAK.

Seizures, not a typical feature of hypoparathyroidism, may present along with myalgia and tetany in patients of hypoparathyroidism. Thorough history and examination, derangement of biochemical parameters such as hypocalcemia, hyperphosphatemia, and inappropriately low levels of parathyroid hormone, along with basal ganglia calcification as seen on imaging, lead to the diagnosis of hypoparathyroidism in a 10-year-old child who presented to us. Treatment with calcium and active vitamin D significantly improved his condition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.7888DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255561PMC

Impact of β-glycerophosphate on the bioenergetic profile of vascular smooth muscle cells.

J Mol Med (Berl) 2020 Jul 2;98(7):985-997. Epub 2020 Jun 2.

Institute for Physiology and Pathophysiology, Johannes Kepler University, Altenberger Strasse 69, 4040, Linz, Austria.

In chronic kidney disease, hyperphosphatemia is a key pathological factor promoting medial vascular calcification, a common complication associated with cardiovascular events and mortality. This active pathophysiological process involves osteo-/chondrogenic transdifferentiation of vascular smooth muscle cells (VSMCs) via complex intracellular mechanisms that are still incompletely understood. Little is known about the effects of phosphate on the bioenergetic profile of VSMCs during the onset of this process. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00109-020-01925-8DOI Listing

Teriparatide (recombinant parathyroid hormone 1-34) enhances bone allograft integration in a clinically relevant pig model of segmental mandibulectomy.

J Tissue Eng Regen Med 2020 Jun 1. Epub 2020 Jun 1.

Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Massive craniofacial bone loss poses a clinical challenge to maxillofacial surgeons. Structural bone allografts are readily available at tissue banks but are rarely used due to a high failure rate. Previous studies showed that intermittent administration of recombinant parathyroid hormone (rPTH) enhanced integration of allografts in a murine model of calvarial bone defect. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/term.3075DOI Listing

Identification of a novel mutation in pseudohypoparathyroidism type Ia in a Chinese family: A case report.

Medicine (Baltimore) 2020 May;99(21):e19965

Department of Endocrinology, The Affiliated Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, P.R. China.

Introduction: Pseudohypoparathyroidism (PHP) indicates a group of rare disorders characterized by end-organ resistance to various hormones, primarily parathyroid hormone (PTH). One of its most common type is PHP-Ia, which is caused by maternally inherited inactivating mutations in GNAS. In this report, we present a Chinese girl with typical features of PHP-Ia and a novel mutation of the GNAS gene. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000019965DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249942PMC

Continuous rhPTH (1-34) treatment in chronic hypoparathyroidism.

Endocrinol Diabetes Metab Case Rep 2020 May 29;2020. Epub 2020 May 29.

Division of Endocrinology and Diabetology, Department of Medicine I, University Hospital Würzburg, Würzburg, Germany.

Summary: Standard treatment of hypoparathyroidism consists of supplementation of calcium and vitamin D analogues, which does not fully restore calcium homeostasis. In some patients, hypoparathyroidism is refractory to standard treatment with persistent low serum calcium levels and associated clinical complications. Here, we report on three patients (58-year-old male, 52-year-old female, and 48-year-old female) suffering from severe treatment-refractory postsurgical hypoparathyroidism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/EDM-20-0009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274549PMC

Supplemental Nicotinamide Dose-Dependently Regulates Body Phosphorus Excretion via Altering Type II Sodium-Phosphate Co-Transporter Expressions in Laying Hens.

J Nutr 2020 May 29. Epub 2020 May 29.

College of Animal Science and Technology, Northwest A&F University, Yangling, Shaanxi, China.

Background: Dietary supplemental nicotinamide is used to treat hyperphosphatemia in humans. However, the mechanisms of its impact on body phosphorus homeostasis remain unclear.

Objective: This study was to determine effects and molecular mechanisms of 3 dietary nicotinamide concentrations on body phosphorus homeostasis in laying hens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jn/nxaa148DOI Listing

A comparative analysis of the efficacy and safety of paricalcitol versus other vitamin D receptor activators in patients undergoing hemodialysis: A systematic review and meta-analysis of 15 randomized controlled trials.

PLoS One 2020 29;15(5):e0233705. Epub 2020 May 29.

Hemodialysis Room, The Fourth Central Hospital of Baoding City, Baoding, Hebei, China.

Paricalcitol, a new vitamin D receptor activator (VDRA), is reported to be more effective than other VDRAs in reducing calcium and phosphorus levels in patients undergoing hemodialysis. However, the efficacy and safety of paricalcitol remain controversial. This analysis compares paricalcitol with other VDRAs in patients undergoing hemodialysis. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0233705PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7259607PMC

Dietary Phosphate Consumption in Australians With Stages 3b and 4 Chronic Kidney Disease.

J Ren Nutr 2020 May 25. Epub 2020 May 25.

Australasian Kidney Trials Network, The University of Queensland, Brisbane, Queensland, Australia; Department of Nutrition and Dietetics, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.

Objective: Dietary phosphate modification is a common therapy to treat hyperphosphatemia in individuals with chronic kidney disease (CKD). However, current dietary intake and common food sources of phosphate typically consumed by individuals with CKD are not well characterized. This study examined a cohort of CKD patients to determine total dietary intake and common food sources of phosphate, including phosphate additives. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.jrn.2020.02.007DOI Listing

Hyperphosphatemic Tumoral Calcinosis: Pathogenesis, Clinical Presentation, and Challenges in Management.

Front Endocrinol (Lausanne) 2020 8;11:293. Epub 2020 May 8.

Skeletal Disorders and Mineral Homeostasis Section, National Institutes of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, United States.

Hyperphosphatemic familial tumoral calcinosis (HFTC) is a rare and disabling disorder of fibroblast growth factor 23 (FGF23) deficiency or resistance. The disorder is manifest by hyperphosphatemia, inappropriately increased tubular reabsorption of phosphate and 1,25-dihydroxy-Vitamin D, and ectopic calcifications. HFTC has been associated with autosomal recessive pathogenic variants in: (1) the gene encoding FGF23; (2) , which encodes a protein responsible for FGF23 glycosylation; and (3) , the gene encoding KLOTHO, a critical co-receptor for FGF23 signaling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fendo.2020.00293DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225339PMC

Simultaneous management of disordered phosphate and iron homeostasis to correct fibroblast growth factor 23 and associated outcomes in chronic kidney disease.

Curr Opin Nephrol Hypertens 2020 Jul;29(4):359-366

Division of Nephrology and Hypertension, Department of Medicine, and Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Purpose Of Review: Hyperphosphatemia, iron deficiency, and anemia are powerful stimuli of fibroblast growth factor 23 (FGF23) production and are highly prevalent complications of chronic kidney disease (CKD). In this manuscript, we put in perspective the newest insights on FGF23 regulation by iron and phosphate and their effects on CKD progression and associated outcomes. We especially focus on new studies aiming to reduce FGF23 levels, and we present new data that suggest major benefits of combined corrections of iron, phosphate, and FGF23 in CKD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MNH.0000000000000614DOI Listing

Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice.

Leuk Lymphoma 2020 May 25:1-6. Epub 2020 May 25.

Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.

The risk of TLS in patients with relapsed CLL treated outside of clinical trials is not well described. Using the Mayo Clinic CLL Database, 48 patients treated with venetoclax for relapsed CLL in routine practice were identified; chart review determined baseline risk for TLS and laboratory abnormalities during venetoclax ramp-up. Overall, 6 (13%) patients developed laboratory TLS, 3 of whom demonstrated clinical TLS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1768384DOI Listing

The absorbing life of bile acids.

Authors:
Joanne Marks

Kidney Int 2020 Jun;97(6):1099-1102

Department of Neuroscience, Physiology and Pharmacology, University College London, London, UK. Electronic address:

Hyperphosphatemia increases cardiovascular complications and all-cause mortality rate in patients with chronic kidney disease. Targeting the processes involved in dietary phosphate absorption is an attractive means for reducing this phosphate burden. We do not, however, fully understand this process and how it is regulated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.kint.2020.03.020DOI Listing

TDAG51 (T-Cell Death-Associated Gene 51) Is a Key Modulator of Vascular Calcification and Osteogenic Transdifferentiation of Arterial Smooth Muscle Cells.

Arterioscler Thromb Vasc Biol 2020 Jul 21;40(7):1664-1679. Epub 2020 May 21.

From the Division of Nephrology, Department of Medicine (K.P., P.F.L., G.G., Š.L., M.E.M., G.P., J.H.B., A.J.I., J.C.K., R.C.A.), McMaster University, and The Research Institute of St. Joseph's Hamilton, ON, Canada.

Objective: Cardiovascular disease is the primary cause of mortality in patients with chronic kidney disease. Vascular calcification (VC) in the medial layer of the vessel wall is a unique and prominent feature in patients with advanced chronic kidney disease and is now recognized as an important predictor and independent risk factor for cardiovascular and all-cause mortality in these patients. VC in chronic kidney disease is triggered by the transformation of vascular smooth muscle cells (VSMCs) into osteoblasts as a consequence of elevated circulating inorganic phosphate (P) levels, due to poor kidney function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/ATVBAHA.119.313779DOI Listing
July 2020
6.000 Impact Factor

Fibroblast growth factor receptor as a potential candidate for phosphate sensing.

Curr Opin Nephrol Hypertens 2020 Jul;29(4):446-452

Department of Molecular Endocrinology, Fujii Memorial Institute of Medical Sciences, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan.

Purpose Of Review: Phosphate plays essential roles in many biological processes. Serum phosphate level needs to be regulated because hypophosphatemia and hyperphosphatemia cause rickets/osteomalacia and ectopic calcification, respectively. Fibroblast growth factor (FGF) 23 is the principal hormone to regulate serum phosphate level. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MNH.0000000000000618DOI Listing

Impact of altered dietary calcium-phosphorus ratio caused by high-phosphorus diets in a rat chronic kidney disease (CKD) model created by partial ligation of the renal arteries.

J Toxicol Pathol 2020 Apr 3;33(2):77-86. Epub 2020 Jan 3.

Department of Food and Nutritional Science, Graduate School of Agriculture, Tokyo University of Agriculture, 1-1-1 Sakura-ga-Oka, Setagaya, Tokyo 156-8502, Japan.

This study aimed to establish a rat chronic kidney disease (CKD) model by studying the effects of a high-phosphorus diet in rats that had undergone partial ligation of the renal arteries (RL). Separate groups of 10-week-old male Slc:Sprague-Dawley rats underwent RL and were fed diets with varying phosphorous levels for a period of 48 days. A marked suppression of body weight gain necessitating humane euthanization occurred on day 28 in rats that had undergone RL and were given high-phosphorus feed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1293/tox.2019-0086DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218233PMC

LED&Paper-based analytical device for phosphatemia/calcemia diagnostics☆.

J Pharm Biomed Anal 2020 Jul 20;186:113321. Epub 2020 Apr 20.

University of Warsaw, Faculty of Chemistry, Pasteura 1, 02-093 Warsaw, Poland.

In this communication a prototype of paper-based analytical device designed for simultaneous determination of orthophosphate and calcium ions, which levels are significant for hyperphosphatemia diagnostics, is presented. The laboratory-on-paper structure for two analytes detection was wax-printed on the surface of filter paper. These two-analyte disposable paper strips are combined with two paired LED-based fluorescence detectors and simple voltmeter used as recorder of analytical signal, what makes the developed device miniature, extremely low-cost, portable and user-friendly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpba.2020.113321DOI Listing

Investigation of nicotinamide as more than an anti-phosphorus drug in chronic hemodialysis patients: a single-center, double-blind, randomized, placebo-controlled trial.

Ann Transl Med 2020 Apr;8(8):530

NHC Key Lab of Hormones and Development (Tianjin Medical University), Tianjin Key Lab of Metabolic Diseases, Metabolic Diseases Hospital & Institute of Endocrinology, Tianjin Medical University, Tianjin 300070, China.

Background: Hyperphosphatemia is a common complication of late-stage chronic kidney disease (CKD). Nicotinamide (NAM) has been reported as an adjunctive therapy for hyperphosphatasemia, but the effect of NAM on fibroblast growth factor 23 (FGF23) and Klotho has rarely been reported.

Methods: We randomly assigned 98 patients who underwent regular hemodialysis to received NAM (0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2020.03.228DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214904PMC

Investigating coherent normalization and dosimetry for the 241Am-La K XRF system.

Physiol Meas 2020 May 11. Epub 2020 May 11.

Department of Physics, Ryerson University, Toronto, Ontario, CANADA.

Lanthanum (La) retention in bone has shown to occur in individuals who are orally administered lanthanum carbonate (LaC), a drug to treat hyperphosphatemia. The breakdown of LaC in the gastrointestinal tract into Laand carbonate ions results in residual quantities of La to deposit in bone. We previously reported a non-invasive x-ray fluorescence (XRF) system that was developed to quantify bone La concentrations and applied it to a series of excised cadaver tibiae. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1088/1361-6579/ab921fDOI Listing

Complex Disease Management: Managing a Cat with Comorbidities.

Authors:
Margie Scherk

Vet Clin North Am Small Anim Pract 2020 Jul 7;50(4):811-822. Epub 2020 May 7.

catsINK, Vancouver BC, Canada. Electronic address:

Many older cats often suffer concurrently from multiple conditions. By focusing on the common concerns, rather than conflicting requirements, a management program can be devised. Optimize hydration, nutrition, and ensure comfort though providing analgesia and a low-stress environment in which the patient's feline-specific nature is respected both in the clinic and at home. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cvsm.2020.03.006DOI Listing

Management of Hyperphosphatemia in End-Stage Renal Disease: A New Paradigm.

J Ren Nutr 2020 May 5. Epub 2020 May 5.

Division of Nephrology and Hypertension, Loyola University Chicago, Maywood, Illinois.

Bone and mineral metabolism becomes dysregulated with progression of chronic kidney disease (CKD), and increasing levels of parathyroid hormone serve as an adaptive response to maintain normal phosphorus and calcium levels. In end-stage renal disease, this response becomes maladaptive and high levels of phosphorus may occur. We summarize strategies to control hyperphosphatemia based on a systematic literature review of clinical trial and real-world observational data on phosphorus control in hemodialysis patients with CKD-mineral bone disorder (CKD-MBD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.jrn.2020.02.003DOI Listing
May 2020
2.548 Impact Factor

The effect of an oral sodium phosphate load on parathyroid hormone and fibroblast growth factor 23 secretion in normo- and hypercalciuric stone-forming patients.

Clin Nutr 2020 Apr 21. Epub 2020 Apr 21.

Department of Dietetics, School of Public Health in Bytom, Medical University of Silesia, Ul. Piekarska 19, 41-902, Bytom, Poland. Electronic address:

Background & Aims: Abnormalities of parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) secretion may cause calcium-phosphate (Ca-P) metabolism disorders in nephrolithiasis. Post-phosphate-load alterations in serum Ca, P and PTH, phosphaturia and calciuria enable monitoring hormonal regulation of Ca-P homeostasis. Our study aimed to determine differences in: 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clnu.2020.04.020DOI Listing

Meta-Analysis Treatment Hyperphosphatemia Chronic Renal Failure Based on Nano Lanthanum Hydroxide.

J Nanosci Nanotechnol 2020 Oct;20(10):6555-6560

Departure of Nephropathy, People's Hospital of Wuwei Gansu Province, Weiwu 733000, Gansu, PR China.

In this study, our aim is to investigate the effect of lanthanum carbonate in chronic treatment renal failure complicated with hyperphosphatemia. Using methods with lanthanum carbonate, hyperphosphatemia, placebos, calcium carbonate, end-stage renal disease as keywords, we searched the Chinese Journal Full-text Database, Chinese sci-tech journal database, Wanfang Data knowledge service platform, web of science, PubMed, and other databases for literature quality; meta analysis was carried out after a subsequent evaluation. The meta analysis results showed a significant difference in the control of the blood phosphorus level between weighted mean difference WMD = -0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1166/jnn.2020.18576DOI Listing
October 2020

Defective O-glycosylation of novel FGF23 mutations in a Chinese family with hyperphosphatemic familial tumoral calcinosis.

Bone 2020 Aug 1;137:115401. Epub 2020 May 1.

Department of Endocrinology, NHC Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China. Electronic address:

Objectives: Hyperphosphatemic familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome (HFTC/HHS) is a rare disorder caused by deficiency or resistance of fibroblast growth factor 23 (FGF23). Here we reported a Chinese family with HFTC/HHS, aiming at clarifying the clinical features, bone microarchitectures and molecular mechanisms of the disease.

Methods: Clinical manifestations, laboratory examinations and genetic analyses were collected from two HFTC patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bone.2020.115401DOI Listing

Nutritional and metabolic parameters of children and adolescents with phenylketonuria.

Clin Nutr ESPEN 2020 Jun 15;37:44-49. Epub 2020 Apr 15.

Programa de Pós-Graduação em Saúde da Criança e do Adolescente, Federal University of Parana, 181 Carneiro St, Alto da Glória, Curitiba, Parana State, 80060-900, Brazil.

Background And Aims: Considering that phenylalanine-poor diets may be monotonous and compromise the development and nutritional status of children and adolescents with phenylketonuria, the aim of this study was to evaluate the anthropometric and biochemical characteristics of children and adolescents with this condition.

Methods: Retrospective study with anthropometric and biochemical data collection from patients with phenylketonuria in the age group 2-19.9 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clnesp.2020.03.024DOI Listing

Serum glucose and phosphorus concentrations during continuous renal replacement therapy using commercial replacement solutions with or without phosphorus.

Hemodial Int 2020 Apr 29. Epub 2020 Apr 29.

Division of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.

Introduction: Continuous venovenous hemofiltration (CVVH) is a common practice in the intensive care unit often associated with electrolyte derangements. Recently, our institution added a phosphate dialysis solution, Phoxillum®, to our formulary as an option for CVVH fluid in addition to the bicarbonate-based Prismasol® products available. We sought to evaluate the impact of Phoxillum in patients who required CVVH when compared to Prismasol with regard to phosphate and glucose management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hdi.12834DOI Listing

A novel long-range deletion spanning STX16 and NPEPL1 causing imprinting defects of the GNAS locus discovered in a patient with autosomal-dominant pseudohypoparathyroidism type 1B.

Endocrine 2020 Jul 26;69(1):212-219. Epub 2020 Apr 26.

Key Laboratory of Endocrinology of the Ministry of Health, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing, China.

Background: Pseudohypoparathyroidism (PHP) is a rare disorder characterized by hypocalcemia, hyperphosphatemia, and resistance to parathyroid hormone (PTH). According to different GNAS mutations, PHP is divided into several subtypes, among which autosomal-dominant PHP1B (AD-PHP1B) is caused by STX16 deletion and epigenetic alteration of GNAS. Although the deletion of STX16 exons 2-6 is commonly observed, other mutations involving STX16 can also result in AD-PHP1B. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12020-020-02304-6DOI Listing

Mid-Term and Long-Term Impact of Permanent Hypoparathyroidism After Total Thyroidectomy.

World J Surg 2020 Aug;44(8):2692-2698

Service of Endocrine and Advanced Laparoscopic Surgery/Department of Surgery, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Vasco de Quiroga 15, Seccion XVI, Tlalpan, 14000, Mexico City, Mexico.

Background: Permanent hypoparathyroidism (PH) is the most frequent long-term complication after total thyroidectomy. PH is related to many short-term and long-term complications, including clinical manifestations of hypocalcemia, hypercalcemia due to overtreatment, hyperphosphatemia, gastrointestinal, neuropsychiatric symptoms, decrease in renal function and infectious complications. The aim of this study was to identify the most frequent effects of PH and its associated risk factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00268-020-05531-0DOI Listing

Hypoparathyroidism.

J Clin Endocrinol Metab 2020 Jun;105(6)

Department of Medicine, Division of Endocrinology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York.

Background: Hypoparathyroidism is a rare endocrine disorder characterized by hypocalcemia and low or undetectable levels of parathyroid hormone.

Methods: This review is an evidence-based summary of hypoparathyroidism in terms of relevant pathophysiological, clinical, and therapeutic concepts.

Results: Many clinical manifestations of hypoparathyroidism are due to the lack of the physiological actions of parathyroid hormone on its 2 major target organs: the skeleton and the kidney. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/clinem/dgaa113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176479PMC